Summary:
Now enrolling: A clinical research study for people with kidney stones – The uriROX-2 Study
Introducing the uriROX-2 Study
If you suffer from kidney stones and are looking to discover what may be causing them, as well as potential new ways to prevent them from returning, the uriROX-2 Study may be an option. It is evaluating an investigational drug designed to potentially help prevent kidney stones in the future.
About the investigational drug
The investigational drug (reloxaliase) is a capsule that is taken by mouth and may work in the stomach and intestine to potentially break down oxalate in food so that less oxalate is absorbed into the bloodstream. Lowering oxalate levels in the urine may decrease the risk of complications of hyperoxaluria, including kidney stones. “Investigational” means that a drug has not been approved by the US Food and Drug Administration or another regulatory authority for treating patients. Investigational drugs can be used only for research purposes.
Who can participate?
You may be able to participate in this study if you are:
- 18 years of age or older
- You have an underlying gastrointestinal condition, such as:
- Bariatric surgery (surgery for weight loss) at least 12 months ago
- Short bowel syndrome
- Pancreatic insufficiency (can occur with pancreatitis, cystic fibrosis and other diseases of the pancreas)
- Inflammatory bowel disease, such as Crohn's disease or Ulcerative Colitis
- Celiac disease
- You have had a documented kidney stone within the last 2 years
All eligible study participants will receive at no cost:
- Study-related lab tests and physical exams
- Study drug
- Compensation for time and travel